Recent Analysts’ Ratings Changes for Strongbridge Biopharma (SBBP)

Several analysts have recently updated their ratings and price targets for Strongbridge Biopharma (NASDAQ: SBBP):

  • 4/11/2019 – Strongbridge Biopharma was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
  • 3/31/2019 – Strongbridge Biopharma was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 3/28/2019 – Strongbridge Biopharma was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
  • 3/27/2019 – Strongbridge Biopharma was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 3/27/2019 – Strongbridge Biopharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.25 price target on the stock. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
  • 3/26/2019 – Strongbridge Biopharma was given a new $15.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 3/25/2019 – Strongbridge Biopharma was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 3/19/2019 – Strongbridge Biopharma had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 3/19/2019 – Strongbridge Biopharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $6.00 price target on the stock. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
  • 3/16/2019 – Strongbridge Biopharma was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
  • 3/2/2019 – Strongbridge Biopharma was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 3/1/2019 – Strongbridge Biopharma was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $5.75 price target on the stock. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
  • 2/28/2019 – Strongbridge Biopharma was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 2/26/2019 – Strongbridge Biopharma was upgraded by analysts at TheStreet from a “d-” rating to a “c-” rating.
  • 2/26/2019 – Strongbridge Biopharma was given a new $12.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 2/26/2019 – Strongbridge Biopharma was given a new $15.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Strongbridge Biopharma stock opened at $4.60 on Wednesday. The stock has a market capitalization of $249.14 million, a PE ratio of 14.84 and a beta of 0.21. Strongbridge Biopharma plc has a 12 month low of $3.82 and a 12 month high of $8.60.

Strongbridge Biopharma (NASDAQ:SBBP) last released its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported $1.64 EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $2.14. The company had revenue of $4.51 million for the quarter, compared to the consensus estimate of $5.03 million. Strongbridge Biopharma had a return on equity of 108.51% and a net margin of 176.69%. As a group, equities research analysts anticipate that Strongbridge Biopharma plc will post -1.52 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in SBBP. 683 Capital Management LLC raised its holdings in shares of Strongbridge Biopharma by 183.2% in the 4th quarter. 683 Capital Management LLC now owns 848,700 shares of the biotechnology company’s stock worth $3,802,000 after purchasing an additional 549,000 shares during the period. Prosight Management LP raised its holdings in shares of Strongbridge Biopharma by 121.3% in the 4th quarter. Prosight Management LP now owns 937,900 shares of the biotechnology company’s stock worth $4,202,000 after purchasing an additional 514,054 shares during the period. 22NW LP purchased a new position in shares of Strongbridge Biopharma in the 4th quarter worth about $1,812,000. Hudson Bay Capital Management LP raised its holdings in shares of Strongbridge Biopharma by 48.1% in the 4th quarter. Hudson Bay Capital Management LP now owns 1,000,000 shares of the biotechnology company’s stock worth $4,480,000 after purchasing an additional 324,900 shares during the period. Finally, Marshall Wace LLP purchased a new position in shares of Strongbridge Biopharma in the 3rd quarter worth about $1,290,000. Institutional investors own 49.10% of the company’s stock.

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

Featured Article: What is the Bid-Ask Spread?

Receive News & Ratings for Strongbridge Biopharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma plc and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit